A synthetic flavone restored vaginal tissue in a preclinical model, offering a potential nonsteroidal treatment for genitourinary syndrome of menopause.
Aurion Biotech's manufacturing approach to unmodified allogeneic corneal endothelial cells offers a set of hard-won lessons for a cell therapy field still working out how to get from proof-of-concept to broad patient access.
A new platform combines engineered viral vectors with the brain's glymphatic system to improve gene delivery to glial cells implicated in multiple neurological disorders.
KCL-286 repaired neuronal DNA damage and reduced neuroinflammation in mice, with prior Phase 1 safety data potentially accelerating its path to Alzheimer's trials.
Philip Wills, Chief Commercial Officer of the Cell & Gene Therapy Division at Catalent, reflects on how the gene therapy industry is evolving from early scientific breakthroughs to commercial maturity.